Vanda Pharmaceuticals
VNDA
A$7.20
Share price
-0.84%
Change (1 day)
-21.34%
Change (1 year)
Categories
Revenue for Vanda Pharmaceuticals (VNDA)
Revenue in 2025 (TTM): A$0.31 Billion
According to Vanda Pharmaceuticals's latest financial reports the company's current revenue (TTM 
) is A$0.30 Billion. In 2024 the company made a revenue of A$0.31 Billion an increase over the revenue in the year 2023 that were of A$0.28 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Vanda Pharmaceuticals from 2009 to 2025
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2025 (TTM) | A$0.31 B | -2.93% |
| 2024 | A$0.31 B | 13.02% |
| 2023 | A$0.28 B | -24.36% |
| 2022 | A$0.37 B | 0.87% |
| 2021 | A$0.37 B | 14.83% |
| 2020 | A$0.32 B | -0.54% |
| 2019 | A$0.32 B | 18.37% |
| 2018 | A$0.27 B | 29.64% |
| 2017 | A$0.21 B | 4.39% |
| 2016 | A$0.20 B | 34.25% |
| 2015 | A$0.15 B | 146.21% |
| 2014 | A$61.28 M | 61.36% |
| 2013 | A$37.98 M | 20.61% |
| 2012 | A$31.49 M | 3.26% |
| 2011 | A$30.49 M | -13.25% |
| 2010 | A$35.15 M | 594.4% |
| 2009 | A$5.06 M |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 Novartis NVS | A$81.57 B | 26,332.45% | 🇨🇭 Switzerland |
 Eli Lilly LLY | A$75.10 B | 24,237.20% | 🇺🇸 USA |
 Johnson & Johnson JNJ | A$136.91 B | 44,265.81% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | A$73.01 B | 23,558.19% | 🇺🇸 USA |
 Pfizer PFE | A$95.73 B | 30,921.95% | 🇺🇸 USA |
 Titan Pharmaceuticals
TTNP | N/A | N/A | 🇺🇸 USA |
 Merck MRK | A$97.97 B | 31,646.55% | 🇺🇸 USA |